Condition
Myeloproliferative neoplasm in accelerated phase (MPN-AP)
Total Trials
1
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Fedratinib
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Unknown1
Clinical Trials (1)
Research Network
Common Treatments
- Fedratinib1
- Onureg 300 Mg Film Coated Tablets1
Active Sponsors
- Martin-Luther-Universitaet Halle-Wittenberg1